Technology
Health
Biotechnology

ADMA Biologics

$4.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-2.13%) Today
-$0.10 (-2.17%) After Hours

Why Robinhood?

You can buy or sell ADMA Biologics and other stocks, options, ETFs, and crypto commission-free!

About

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. Read More The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Employees
318
Headquarters
Ramsey, New Jersey
Founded
2006
Market Cap
217.86M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
547.07K
High Today
$4.73
Low Today
$4.37
Open Price
$4.73
Volume
604.73K
52 Week High
$6.96
52 Week Low
$2.08

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Manufacturing
Pharmaceutical
2013 IPO

News

Yahoo Finance14h

Largest Insider Trades of the Week

- By Tiziano Frateschi The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the insiders tab, change the settings for All Insider Buying to "$200,000+," the duration to "May 2019" and All Insider Sales to "$200,000+." According to these filters, the following are trades from company insiders this week. Perceptive Life Sciences Master, 10% owner of ADMA Biologics Inc. (ADMA), bought 4 million shares for an average price of $4 per share on May 21. 273c5150...

94
Seeking AlphaMay 22

ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside

ADMA should see significant upside during the second half of 2019 as Ascenvi and Bivigam hit the market in force. ADMA's market capitalization does not reflect the earnings power of its newly approved products; its valuation currently also ignores an expansive pipeline. A recent dilutive stock offering, as well as significant non-dilutive debt funding, has improved ADMA's cash position to more than $100 million, more than enough to scale production and marketing. Since April, ADMA has won approval for tw...

290
Yahoo FinanceMay 21

Adma Biologics Inc President and CEO Adam S Grossman Bought $120,000 of Shares

- By insider President and CEO of Adma Biologics Inc (ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share. The total cost of this purchase was $120,000. ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. ADMA Biologics Inc has a market cap of $193.870 million; its shares were traded at arou...

290

Earnings

-$0.59
-$0.47
-$0.36
-$0.24
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.